Experimental Drug Shows Promise in Slowing Disability from Multiple Sclerosis
-
April 9, 2025
- HealthDayTV HealthDay Reporter
Results of a phase 3 clinical trial show an experimental drug called tolebrutinib can delay disability in patients with non-relapsing secondary progressive multiple sclerosis.
Health News is provided as a service to Cooperative Health Pharmacy site users by HealthDay. Cooperative Health Pharmacy nor its employees, agents, or contractors, review, control, or take responsibility for the content of these articles. Please seek medical advice directly from your pharmacist or physician.
Copyright © 2025 HealthDay All Rights Reserved.